LGLong Gao

Long Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Long Gao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated Bile Metabolomics and Serum Biomarkers for Differentiating Cholangiocarcinoma from Cholelithiasis

    by Jinduo Zhang, Leiqing Wang, Xu Zhang, Ping Yue, Boru Jin, Ningning Mi, Jinyu Zhao, Long Gao, Dylan Lee, Yanyan Lin, et al.

    Background: We investigated bile metabolites and serum variables for differentiating cholangiocarcinoma (CCA) from cholelithiasis. Methods: Bile from 31 patients with CCA and 48 with cholelithiasis was profiled by high-resolution LC-MS. Candidate metabolites and serum variables were integrated in a seven-variable classifier, and public single-cell data provided tissue-level biological context. Results: Of 2269 annotated metabolite features, 532 met the exploratory screening criteria. The selected signature comprised pyruvic acid, lipoxin A4, CEA, APOA1, 3-chloro-L-tyrosine, ADP-ribose, and glutaric acid; pyruvic acid had the largest contribution in the SHAP analysis. Random forest achieved an AUC of 0.894 in the classifier comparison, a training cross-validation AUC of 0.820, and an AUC of 0.914 in the 16-patient test subset. Because selection used all 79 patients before evaluation, these internal performance estimates may be optimistic. Conclusions: Integrated bile and serum profiling identified a promising seven-variable signature for differentiating CCA from cholelithiasis in this cohort. Added diagnostic value over routine serum markers and performance in other benign biliary conditions have not been established.

  • Open Access

    Evaluation and investigation of the cardiotoxicity of the potential anti-cholangiocarcinoma drug lanatoside C

    by Yu-Hai Ma, Chong-Fei Huang, Hai-Dong Ma, Jin-Yu Zhao, Wen-An Wang, Zi-He Dong, Yi Shao, Long Gao, Jian-Jun Chen, Wen-Bo Meng

    Objective: Lanatoside C (Lan C), a cardiac glycoside, has demonstrated potent anti-cholangiocarcinoma activity. However, its potential cardiotoxicity at therapeutic doses remains poorly understood. This study aimed to systematically evaluate the cardiotoxicity of Lan C at cellular and organ levels and to elucidate its underlying molecular mechanisms. Methods: Human AC16 cardiomyocytes (ATCC® CRL-3568™) were employed for in vitro studies, with untreated cells included as negative controls. Cytotoxic effects at anti-cholangiocarcinoma-relevant concentrations (50–200 nM) were evaluated using a combination of cell viability assays, transmission electron microscopy, flow cytometry for apoptosis and reactive oxygen species (ROS) detection, JC-1 staining to assess mitochondrial membrane potential, lactate dehydrogenase (LDH) release assays, and Western blot analysis of apoptotic proteins. Male BALB/c mice were administered either vehicle (PBS) or Lan C (80 mg/kg/day) by oral gavage for 28 consecutive days. Cardiac function was assessed by echocardiography, and myocardial architecture was examined through histopathological analysis. Results: Lan C showed a dose-dependent inhibitory effect in vitro on AC16 cell viability and induced apoptosis. This process involved decreased mitochondrial membrane potential, increased reactive oxygen species (ROS), downregulation of the anti-apoptotic protein Bcl-2, and upregulation of cytochrome C, Cleaved Caspase-9, and Cleaved Caspase-3, indicating activation of the mitochondrial-dependent apoptotic pathway. In vivo , high-dose Lan C significantly impaired left ventricular systolic function, as indicated by reductions in LVEF and LVFS, and induced myocardial structural alterations. Conclusion: Lan C exhibits measurable but relatively low cardiotoxicity at concentrations effective against cholangiocarcinoma, with cardiac effects may be manageable at therapeutic doses. These findings support Lan C as a promising anti-tumor candidate with controllable cardiotoxicity under optimized dosing and clinical monitoring.